Raghav, K., Siena, S., Takashima, A., Kato, K., van den Eynde, M., Pietrantonio, F., … Yoshino, T. (2025). 737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial. In Annals of Oncology (Vol. 36, pp. S514–S515). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1311

Raghav, K., S. Siena, A. Takashima, K. Kato, M. van den Eynde, F. Pietrantonio, Y. Komatsu, et al. “737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial.” In Annals of Oncology, 36:S514–15. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1311.

Raghav K, Siena S, Takashima A, Kato K, van den Eynde M, Pietrantonio F, et al. 737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial. In: Annals of Oncology. Elsevier BV; 2025. p. S514–5.

Raghav, K., et al. “737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S514–15. Crossref, doi:10.1016/j.annonc.2025.08.1311.

Raghav K, Siena S, Takashima A, Kato K, van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, André T, Lonardi S, Yamaguchi K, Tie J, Gravalos Castro MC, Strickler JH, Barrios D, Goodman E, Kamio T, Abe K, Yoshino T. 737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial. Annals of Oncology. Elsevier BV; 2025. p. S514–S515.